10x Genomics (TXG) news
Recent news
10X Genomics: Jury found all patents valid, enforceable
AInvest Wire · 2d ago10X Genomics - To seek enhanced damages and permanent injunction against Parse in U.S.
10x Genomics (Nasdaq: TXG) has secured a permanent injunction against Parse Biosciences, preventing the latter from manufacturing, using, selling, or offering its ATAC and ATAC-Multiome Single Cell products in the United States and globally. The injunction, issued under a consent agreement entered…
AInvest Wire · 2d ago10X Genomics - Jury awards co over $4.80 mln in damages for infringing sales Feb 2021-June 30, 2026
AInvest Wire · 2d ago10X Genomics wins patent infringement verdict against Parse Biosciences
10x Genomics and Parse Biosciences remain embroiled in a high-stakes legal battle over single-cell sequencing patents, with recent rulings delivering mixed outcomes for both parties. On August 19, the U.S. Court of Appeals for the Federal Circuit upheld the Patent Trial and Appeal Board’s (PTAB)…
AInvest Wire · 2d agoStifel raises target price for 10X Genomics Inc. to $50 from $25
Stifel Nicolaus has raised its price target for 10X Genomics Inc. (NASDAQ: TXG) to $50 from $25, while maintaining a Buy rating . The firm cited strong product adoption, particularly for the company’s Flex Apex platform, following the recent AGBT conference in Florida. Stifel also noted positive…
AInvest Wire · Aug 7, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.